Phase II Sunitinib Prog Met AIPC
This study has been completed.
Information provided by (Responsible Party):
US Oncology Research
First received: January 11, 2008
Last updated: October 13, 2016
Last verified: October 2016
The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.
Metastatic Prostate Cancer
||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Primary Outcome Measures:
- Median Progression-free Survival (PFS) Time at 1-year. [ Time Frame: 12 months ]
PFS is measured from the date of registration to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Secondary Outcome Measures:
- Overal Survival (OS) Rate at 1-year. [ Time Frame: 12 months ]
OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.
- Prostate Specific Antigen (PSA) Response [ Time Frame: 12 months ]
PSA value declined to 50% when compared to the value at the baseline.
- Change of PSA Doubling Time [ Time Frame: Baselie and up to 12 months ]
Difference of PSA doubling time between baseline and end of the treatment.
- Objective Response Rate (ORR) st [ Time Frame: 12 months ]
OORR = Complete Response (CR) + Parcial response (PR). CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.RR = Completed response (CR) + Partial response (PR).
- Percentage of Participants With Decrease in Present Pain Intensity (PPI) From Baseline. [ Time Frame: 12 months ]
Pain score decreased >=2 points from baseline. The PPI scale has the following descriptors: 0=no pain, 1=mild pain, 2=discomforting pain, 3=distressing pain, 4=horrible pain, and 5=excruciating pain. The patient will be asked to self-assess and record their PPI in the study diary. Upon diary review, the study nurse will utilize the PPI daily scores to calculate the week's average. The weekly PPI score during the study is the average of the daily PPI scores, based on a minimum of 3 daily PPI assessments during a week's period.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||June 2009 (Final data collection date for primary outcome measure)
Experimental: Sunitinib Malate
Sunitinib Malate (Sutent) (50 mg/day on Days 1-28 of 42-day cycles)
50 mg/day orally each of Days 1-28 of each 6 week cycle
The following rationale can be made for a Phase II trial to evaluate sunitinib malate (Sutent) for the therapy of progressive metastatic androgen-independent prostate cancer (AIPC) following prior docetaxel chemotherapy. Since most patients with metastatic AIPC following prior chemotherapy clinically progress rapidly, we believe that achieving a 30% freedom from clinical progression (PFS) (not including PSA progression) at 12 weeks represents biologically active therapy. Sunitinib malate (Sutent) represents a tolerable and convenient form of therapy with the potential for improving outcomes in AIPC.
|Ages Eligible for Study:
||18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- A patient will be eligible for inclusion in this study if he meets all of the following criteria:
- Histologically confirmed, adenocarcinoma of the prostate
- Stage IV(metastatic) disease, documented on CT, MRI, or X-ray
- Progressive disease (PSA or clinical): PSA progression defined as baseline increase followed by any serial increase after 2 weeks; clinical progression by symptomatic or radiologic criteria.
- An elevated PSA level of for patients progressing by PSA criteria is required
- Currently on androgen ablation hormone therapy (an LHRH agonist or orchiectomy) with testosterone level <50ng/dL)
- Has received 1 or 2 prior chemotherapy regimens (no more than 2). One prior regimen must be docetaxel.
- Has an ECOG Performance Status (PS) 0-2
- Is greater than 18 years of age
- Meets protocol defined laboratory values
- Has adequate cardiac function in the opinion of the Investigator
- Has no uncontrolled arrhythmia or hypertension
- Resolution of all acute toxic effects of prior chemotherapy or surgical procedures to NCI CTCAE Version 3.0 Grade less than 1, in the opinion of the Treating Physician
- If fertile, patient has agreed to use an acceptable method of birth control to prevent pregnancy for the duration of the study and for a period of 2 months thereafter
- Has signed a Patient Informed Consent Form
- Has signed a Patient Authorization Form
- A patient will be excluded from this study if he meets any of the following criteria:
- Has any disease other than that described in inclusion criterion #1
- Had prior treatment with Sutent
- Has not received prior docetaxel for the current disease
- Has received any prior radionuclide therapy
- Has received prior radiation to >50% of the bone marrow
- Is receiving concurrent immunotherapy
- Has a history of hypersensitivity to any of the components of Sutent: mannitol, croscarmellose sodium, povidone (K-25) and magnesium stearate as inactive ingredients. The orange gelatin capsule shells contain titanium dioxide, and red iron oxide. The caramel gelatin capsule shells also contain yellow iron oxide and black iron oxide. The printing ink contains shellac, propylene glycol, sodium hydroxide, povidone and titanium dioxide.
- Has had significant bleeding in previous 4 weeks
- Has had any of the following within the prior 6 months: severe/unstable angina, myocardial infarction, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident, transient ischemic attack, or pulmonary embolism
- Is receiving concurrent bisphosphonate therapy; long-standing bisphosphonate therapy (initiated >8 weeks prior to registration) is acceptable. Bisphosphonates started within the prior 8 weeks will not be allowed since this may affect other study endpoints and render their interpretation difficult
- Has received treatment with radiation therapy, surgery, chemotherapy, ketoconazole, corticosteroids, or an investigational agent within 4 weeks prior to registration, (6 weeks for radiation therapy, nitrosureas or Mitomycin C)
- Has uncontrolled arrhythmia or hypertension
- Has evidence of uncontrolled CNS involvement (previous radiation and off steroids is acceptable)
- Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
- Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
- Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin), which could affect the diagnosis or assessment of any of the study drugs
- Is unable to comply with requirements of study
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00599313
US Oncology Research
||Guru Sonpavde, MD
||US Oncology Research
||US Oncology Research
History of Changes
|Other Study ID Numbers:
2006-0012 ( Other Identifier: Pfizer )
|Study First Received:
||January 11, 2008
|Results First Received:
||January 20, 2016
||October 13, 2016
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 28, 2017
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male
Angiogenesis Modulating Agents
Physiological Effects of Drugs